跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 106 条关于
“OMERS”
全部
106
临床试验
65
药物
16
机构
4
资讯
21
9个月前
Ultragenyx Advances Multiple Gene Therapies Toward Regulatory Approval with DTX401 BLA Submission
11个月前
ARS Pharmaceuticals Secures $250 Million Loan Facility to Accelerate Neffy Commercialization
2年前
Verona Pharma's Ohtuvayre (ensifentrine) Receives FDA Approval for COPD Maintenance Treatment
去年
BioCryst Pharmaceuticals Divests European ORLADEYO Rights for $264 Million to Achieve Debt-Free Status
去年
ARS Pharmaceuticals Reports Strong Q3 2025 Growth for Needle-Free Epinephrine Nasal Spray neffy
去年
MVA-MERS-S Vaccine Shows Safety and Efficacy in Phase Ib Trial Against MERS-CoV
去年
Omeros' Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy
去年
Omeros' Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy
8个月前
Omeros Receives FDA Approval for First-in-Class TA-TMA Therapy YARTEMLEA
去年
FDA Grants Rare Pediatric Disease Designation to Omeros' Zaltenibart for C3 Glomerulopathy
第 1 页,共 3 页
上一页
下一页